Anuh Pharma (BOM:506260) has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for Sulfadimethoxine, according to a BSE filing on Friday.
The CEP for Sulfadimethoxine will provide the company access to regulated markets.
The company's shares were up over 2% in recent trade.